Quarterly ResultMay 6, 2026, 04:38 PM
BIO-TECHNE Q3 Net Earnings +126% to $51.0M; EPS $0.33
AI Summary
BIO-TECHNE Corp reported a significant increase in net earnings and diluted EPS for the third quarter of fiscal year 2026, despite a slight dip in net sales. Net earnings surged by 126.0% to $51.0 million, with diluted EPS rising to $0.32. This strong profit growth was primarily driven by a substantial reduction in selling, general and administrative expenses, which decreased by 27.7%. The company also improved its financial position by reducing long-term debt obligations by 42.2% and increasing cash and cash equivalents by 29.4%.
Key Highlights
- Net earnings for Q3 2026 increased by 126.0% to $51.0 million from $22.6 million in Q3 2025.
- Diluted EPS for Q3 2026 rose by 135.7% to $0.32 from $0.14 in Q3 2025.
- Net sales for Q3 2026 decreased by 1.5% to $311.4 million from $316.2 million in Q3 2025.
- Operating income for Q3 2026 increased by 95.0% to $75.5 million from $38.7 million in Q3 2025.
- Selling, general and administrative expenses decreased by 27.7% to $109.3 million in Q3 2026.
- Long-term debt obligations decreased by 42.2% to $200.0 million as of March 31, 2026.
- Cash and cash equivalents increased by 29.4% to $209.8 million as of March 31, 2026.
- Net cash from operating activities for the nine months ended March 31, 2026, increased by 3.9% to $196.7 million.
Price Impact
More from TECH